BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9384683)

  • 1. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
    Tafuri A; De Felice L; Petrucci MT; Mascolo MG; Ricciardi MR; Ciliberti C; Martelli MP; Petti MC
    Cytokines Mol Ther; 1995 Dec; 1(4):301-7. PubMed ID: 9384683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
    Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
    Hubeek I; Litvinova E; Peters GJ; Broekhuizen R; Haarman EG; Huismans DR; Cloos J; Zwaan CM; Fleischhack G; Creutzig U; Kaspers GJ
    Int J Oncol; 2004 Dec; 25(6):1823-9. PubMed ID: 15547723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
    Visani G; Tosi P; Zinzani PL; Manfroi S; Ottaviani E; Testoni N; Clavio M; Cenacchi A; Gamberi B; Carrara P
    Leukemia; 1994 Nov; 8(11):1842-6. PubMed ID: 7526088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
    Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
    Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
    Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
    Bashey A; Liu L; Ihasz A; Medina B; Corringham S; Keese K; Carrier E; Castro JE; Holman P; Lane TA; Hassidim K; Ball ED
    Leuk Res; 2006 Apr; 30(4):503-6. PubMed ID: 16303178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
    Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
    N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
    Baek JH; Sohn SK; Kim DH; Kim JG; Yang DH; Kim YK; Lee JJ; Kim HJ
    Acta Haematol; 2007; 117(2):109-14. PubMed ID: 17135724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modified FLAG regimen in the management of refractory acute myeloid leukemia].
    Yang LJ; Meng FY; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Xu D; Sun J; Liu QF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Oct; 23(10):1054-5. PubMed ID: 14559692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.